CN Patent

CN115485277A — 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶

Assigned to Boehringer Ingelheim International GmbH · Expires 2022-12-16 · 3y expired

What this patent protects

本发明涉及式(I)的新的[1,3]二嗪基[5,4‑d]嘧啶及其衍生物，其中基团R 1 、R 2 、R 3 及R 4 具有权利要求书和说明书中所给出的含义；涉及其作为HER2及其突变体的抑制剂的用途；涉及含有此类化合物的药物组合物；及其作为药物，尤其是作为用于治疗和/或预防致癌疾病的药剂的用途。

USPTO Abstract

本发明涉及式(I)的新的[1,3]二嗪基[5,4‑d]嘧啶及其衍生物，其中基团R 1 、R 2 、R 3 及R 4 具有权利要求书和说明书中所给出的含义；涉及其作为HER2及其突变体的抑制剂的用途；涉及含有此类化合物的药物组合物；及其作为药物，尤其是作为用于治疗和/或预防致癌疾病的药剂的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN115485277A
Jurisdiction
CN
Classification
—
Expires
2022-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.